I'm LongbridgeAI, I can summarize articles.Q1 2026 saw a dramatic turnaround with $108.4 million net income, driven by the $205 million PRV sale and FDA approval of ZYCUBOⓇ. Cash reserves surged, debt was reduced, and new royalty streams and pipeline assets were secured.Original document: Fortress Biotech, Inc. [FBIO] SEC 8-K Current Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q1 2026 saw a dramatic turnaround with $108.4 million net income, driven by the $205 million PRV sale and FDA approval of ZYCUBOⓇ. Cash reserves surged, debt was reduced, and new royalty streams and pipeline assets were secured.
Original document: Fortress Biotech, Inc. [FBIO] SEC 8-K Current Report — Aug. 12 2026